Global Neomycin Sulphate Market Size, Share, and COVID-19 Impact Analysis, By Dosage Form (Oral, Injectable, and Topical), By Purity (USP Grade, BP Grade, and EP Grade), By Application (Antibacterial Drugs, Veterinary Applications, Cosmetics & Personal Care Products, and Industrial & Agricultural Chemicals), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Neomycin Sulphate Market Size Insights Forecasts to 2035

• The Global Neomycin Sulphate Market Size Was Valued at USD 298.81 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 5.87% from 2025 to 2035
• The Worldwide Neomycin Sulphate Market Size is Expected to Reach USD 559.42 Million by 2035
• Asia Pacific is expected to Grow the fastest during the forecast period.

According to a Research Report Published by Spherical Insights and Consulting, The Global Neomycin Sulphate Market Size was worth around USD 298.81 Million in 2024 and is predicted to Grow to around USD 559.42 Million by 2035 with a compound annual growth rate (CAGR) of 5.87% from 2025 to 2035. The worldwide neomycin sulphate market shows growth because more people get bacterial infections, hospitals and clinics, and pharmaceutical companies increase their use of topical and ophthalmic antibiotics, healthcare facilities improve their treatment capabilities, and people become more aware of antimicrobial therapies, and scientists develop new drug delivery systems.

Market Overview

Neomycin sulphate serves as an extensive antibiotic treatment, which veterinarians and doctors use to treat bacterial infections in both humans and animals. The medication functions effectively and economically, which makes it a preferred choice for skin infection treatment in topical creams and ointments and for eye and ear treatment in ophthalmic and otic solutions and for gastrointestinal disorder management in oral medicines that decrease intestinal bacteria before surgery. The worldwide market receives its main business force from two factors, which are the increasing number of infectious diseases and the rising need for agricultural antibiotics used in poultry and livestock, together with the growing development of health facilities.

Dairy Australia provided its comments to the Australian Pesticides and Veterinary Medicines Authority about the proposed registration revaluation of neomycin for oral, intramammary, and injectable medical products, which they plan to evaluate in May 2024. The review process has the potential to modify or revoke essential veterinary antibiotic authorizations, which will have economic effects on the dairy sector that Dairy Australia values at A$6.1 billion. The upcoming markets provide business possibilities because people require better hygiene standards, and researchers create new treatment methods that combine different approaches. The main companies in the industry, which include Pfizer Limited, Perrigo Company, Myland Pharma, and various Asian manufacturers, are working to create strategic alliances while they expand their production capabilities and manage multiple regulatory complexities.

Report Coverage

This research report categorizes the neomycin sulphate market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the neomycin sulphate market. Recent market developments and competitive strategies, such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the neomycin sulphate market. 

Driving Factors

The global neomycin sulphate market is primarily driven by the rising prevalence of bacterial infections and the resulting demand for broad-spectrum antibiotics in human and veterinary medicine. The pharmaceutical industry in human healthcare sees product demand growth through the development of topical drugs, ophthalmic solutions, and ointment products. The veterinary sector drives market growth because it controls more than 50 percent of market share through increasing industrial livestock and poultry production, and the need for gastrointestinal treatments. The market continues to expand because developing countries build new healthcare facilities and neomycin proves more affordable than advanced treatment options.

Restraining Factors

The global neomycin sulphate market faces two major restraining factors through its two main elements, which include severe adverse side effects that cause nephrotoxicity and ototoxicity and control medical use. Market growth faces three major obstacles, which include strict regulatory requirements, the rise of antibiotic resistance, which decreases product effectiveness and the increasing presence of safer alternative antibiotics for human and veterinary use.

Market Segmentation

The neomycin sulphate market share is classified into dosage form, purity, and application.  

• The oral segment dominated the market in 2024, approximately 45% and is projected to grow at a substantial CAGR during the forecast period.

Based on the dosage form, the neomycin sulphate market is divided into oral, injectable, and topical. Among these, the oral segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The oral segment dominated the market growth due to it provides effective gastrointestinal infection treatment, being used for pre-surgical bowel preparation, and allowing easy administration to patients. The hospital admission increase, together with rising awareness about bacterial infection treatment and doctors' ongoing preference for oral antibiotics, resulted in high demand for oral neomycin sulphate products.

• The USP grade segment accounted for the largest share in 2024, approximately 54% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the purity, the neomycin sulphate market is divided into USP grade, BP grade, and EP grade. Among these, the USP grade segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The USP grade segment accounted for the largest share because it provides high purity combined with strict quality requirements and extensive regulatory acceptance, which is especially true in North America. The market maintained its growth because pharmaceutical formulations found their use, manufacturers constructed their business around it, and it provided consistent efficacy with patient safety protection.

• The antibacterial drugs segment accounted for the highest market revenue in 2024, approximately 60% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the application, the neomycin sulphate market is divided into antibacterial drugs, veterinary applications, cosmetics & personal care products, and industrial & agricultural chemicals. Among these, the antibacterial drugs segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The antibacterial drugs segment market grows because bacterial infections increased, the demand for topical and ophthalmic antibiotics has grown, and healthcare access expanded throughout the world. The segment growth received support from hospitals using neomycin sulphate as a standard treatment method, while people became more knowledgeable about infection control practices.

Regional Segment Analysis of the Neomycin Sulphate Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the neomycin sulphate market over the predicted timeframe.

North America is anticipated to hold the largest share of the neomycin sulphate market over the predicted timeframe. Neomycin sulphate market share in North America will become the 40% share because the region possesses advanced healthcare systems, high antibiotic consumption and strict regulatory frameworks which ensure product safety and quality control. The United States leads the region because it needs topical and ophthalmic antibiotics and has strong pharmaceutical manufacturing and extensive hospital networks, while Canada supports the market through its established healthcare systems and rising antimicrobial stewardship awareness. The New York State Department of Health identified the dangers of antibiotic overuse in November 2025 when it announced better prescription practices for children and adults, although the CDC documents 2 million cases of resistant infections and more than 23,000 annual deaths.

Asia Pacific is expected to grow at a rapid CAGR in the neomycin sulphate market during the forecast period. The neomycin sulphate market will experience a 21% share in rapid growth in the Asia Pacific due to increasing bacterial infections, expanding healthcare systems and greater availability of budget-friendly antibiotics. China and India drive market expansion through their large populations and pharmaceutical manufacturing capabilities, and increasing domestic consumption, while Japan and South Korea benefit from their advanced healthcare systems and growing use of ophthalmic and topical antibiotics. India introduced NAP-AMR 2.0 in November 2025 as a One Health plan that improves surveillance and infection control and responsible antibiotic use, while it indirectly impacts neomycin sulphate regulation and market development.

The neomycin sulphate market in Europe shows continuous market expansion because people understand antimicrobial resistance better, and Europe possesses advanced healthcare systems and high usage of topical and ophthalmic antibiotics. The top three countries in this field are Germany, France, and the UK because they maintain strong hospital systems, implement strict regulations and invest in pharmaceutical research. In May 2024, the UK and other countries introduced their updated National Action Plans on AMR, which enforced new antibiotic regulations, established better monitoring systems and created research incentives to develop new drugs while promoting responsible use of antibiotics that affects the demand for neomycin sulphate.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the neomycin sulphate market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Pfizer Limited
• Alcon Inc.
• Perrigo Company plc
• Bausch & Lomb Incorporated
• Myland Pharma
• Sanofi S.A.
• Xgen Pharmaceuticals
• Shandong Qifa
• Nostrum Laboratories Inc
• GlaxoSmithKline plc
• Merck & Co., Inc.
• AstraZeneca plc
• Novartis AG
• Medimetriks Pharmaceuticals, Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In October 2025, Amneal Pharmaceuticals received FDA approval for a new generic otic solution combining neomycin sulphate, polymyxin B, and hydrocortisone to treat outer ear infections. This approval expands affordable access to effective combination therapies, offering patients a cost-effective alternative for managing bacterial ear infections.

• In November 2024, Health Canada announced a recall of three lots of Oridermyl Ointment (Neomycin Sulfate 3500 unit/g. Nystatin 100000 unit/g, Permethrin 10mg/g, Triamcinolone Acetonide 1mg/g) by Vetoquinol N. A. Inc. due to possible out-of-specification Triamcinolone acetonide levels. The ointment, used to treat otitis externa and secondary infections in cats and kittens, is being withdrawn from wholesalers as a precaution.

• In April 2025, Nordic Pharma partnered with Harrow to launch an authorized generic of Maxitrol (neomycin, polymyxin B, dexamethasone) for bacterial eye infections. Maxitrol and its generics recorded USD 20.8 million in U.S. annual sales as of January 2025, enhancing affordable access to ophthalmic treatments.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the neomycin sulphate market based on the below-mentioned segments:

Global Neomycin Sulphate Market, By Dosage Form

• Oral
• Injectable
• Topical

Global Neomycin Sulphate Market, By Purity

• USP Grade
• BP Grade
• EP Grade

Global Neomycin Sulphate Market, By Application

• Antibacterial Drugs
• Veterinary Applications
• Cosmetics & Personal Care Products
• Industrial & Agricultural Chemicals

Global Neomycin Sulphate Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa